Article
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Clinical lung cancer - 1 Sept 2016
Martin Petra, Stewart Erin, Pham Nhu-An, Mascaux Celine, Panchal Devang, Li Ming, Kim Lucia, Sakashita Shingo, Wang Dennis, Sykes Jenna, Friess Thomas, Shepherd Frances A, Liu Geoffrey, Tsao Ming-Sound
Abstract excerpt
BACKGROUND: The epidermal growth factor receptor (EGFR) kinase domain T790M (amino acid substitution at position 790 in EGFR from threonine [T] to methionine [M]) mutation in non-small-cell lung cancer (NSCLC) results in resistance to EGFR tyrosine kinase inhibitors (TKIs). We used a patient-derived tumor xenograft (PDX) model containing an EGFR exon 19 deletion/T790M mutation to assess response to the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.